This message contains images. If you don't see images, click here to view.
Advertise in this news brief.




Text Version    RSS    Subscribe    Unsubscribe    Archive    Media Kit    July 23, 2014


 




Proposed 2015 Medicare Physician Fee Schedule (PFS) changes for 2015

By Margaret Havens Neal MD, FSP President Elect

On July 3, the Centers for Medicare and Medicaid Services (CMS) issued the proposed 2015 Medicare physician fee schedule (PFS) regulation. The following issues included in the 2015 proposed rule are the ones of specific concern to pathologists and laboratories. These proposals are currently in the comment period and the CAP is working on their responses for pathology. The final rule, that takes effect January 1, 2015, is scheduled for release around November 1.

READ MORE



Will CMS exempt pathologists from meaningful use penalties?
EHR Intelligence
Pathologists may be used to seeking out irregularities under the microscope, but with the support of Congress, they might also be staring at a relief from the financial penalties incurred by non-participation in the EHR Incentive Programs. With cuts to Medicare payments soon to begin for those who do not attest to meaningful use, the College of American Pathologists is arguing for an expansion of the hardship exemption to include immunity to future payment reductions in a letter to CMS Administrator Marilyn Tavenner.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Capturing cancer: a powerful new technique for early diagnosis
Bioscience Technology
Despite impressive medical strides, cancer remains a leading killer and overwhelming burden to healthcare systems, causing well over a half million fatalities per year, with a projected cost of $174 billion by 2020, according to the National Cancer Institute. Reducing the human and economic toll will require diagnosis and intervention at early stages of illness, when the best prognosis for a cure exists.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Thousands of National Health Service patients to have DNA sequenced to help cancer research
The Independent
A pioneering project that could one day help cure cancers and rare genetic diseases by sequencing the DNA of up to 100,000 NHS patients is one step closer. The U.K. government has chosen an American gene-sequencing company, Illumina, to carry out the sequencing at its site in Cambridgeshire, it has emerged. Regulatory papers filed in the U.S. confirm a contract is in the final stages of negotiation for the £100 million project.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


HHS OIG finds Medicare paid $1.7 billion in suspect clinical lab claims
California Healthline
In 2010, Medicare made at least $1.7 billion in questionable Part B payments for clinical laboratory claims that had at least one red flag, such as an ineligible physician identification number or duplicate tests, according to a report released by the HHS Office of Inspector General, the Wall Street Journal reports. According to the Journal, Medicare is the largest payer of clinical lab services — such as blood counts, cholesterol screenings and urinalyses — in the nation.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


HIE use and EHR adoption rise, but interoperability elusive for hospitals, physicians, clinical labs and pathology groups
Dark Daily
Pathologists tracking the adoption of EHR systems by hospitals and physicians will be interested to learn that, according to the federal government, more than 80 percent of hospitals and 50 percent of physicians now use these products. It is also reported that growing numbers of providers are exchanging data with health information exchanges. Clinical laboratories and anatomic pathology groups have a big stake in these developments. Medical laboratory test data is an essential component to every patient’s permanent health record, which is why it is important for every lab to have interfaces with the HIEs serving their communities and regions.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


The future of cancer genomics
Genetic Engineering News
As you have probably noticed, there’s been a major shift in the focus of next-gen sequencing over the past couple of years. First it was all about new genomes, new techniques and discovery. Now it's all about translation. We are entering a new era in next-gen sequencing, one in which NGS technologies will not only be used for discovery, but will be integrated into clinical care.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Study: When doctors communicate, cancer care costs drop 34 percents
The Tennessean
Results from a new study show both the promise and the difficulty of reducing the cost of cancer care. The study, published in the Journal of Oncology Practice, looked at 810 patients with various types of cancer, and was the result of a collaboration between an insurer, UnitedHealthcare and five oncology providers across the country. For the project, United compensated physicians differently than is the normal practice.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


63 percent of practice management software purchases are replacements
EHR Intelligence
EHRs aren't the only piece of health IT getting a makeover in a large number of healthcare organizations: providers are currently ripping out and replacing practice management and revenue cycle management software in a bid to modernize their infrastructure and meet the challenges of ICD-10, accountable care and compliance with other regulatory initiatives, including meaningful use.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Removing both breasts may not improve survival from breast cancer
TIME
Researchers at the University of Minnesota confirm that when it comes to treating some forms of breast cancer, drastic surgery to remove breast tissue may not help in improving survival from the disease. Reporting in the Journal of the National Cancer Institute, the scientists describe a model for calculating life expectancy based on recent rates of recurrent cancers among women with stage 1 or stage 2 disease.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE

Disclaimer: The authors, editors, and the Florida Society of Pathologists (FSP) Executive Committee affiliated with "Florida Pathology Today" e-Newsletter cannot and do not warrant the completeness, accuracy, non-infringement, merchantability, timeliness or fitness for a particular purpose of the information or views contained within this publication, or available through the links provided within articles contained within this publication.

FSP has no control over and does not officially endorse the content of the information available on the links contained in the "Florida Pathology Today" or links imbedded in articles within the "Florida Pathology Today." These links are provided as a courtesy only. Linked sites are not a part of the "Florida Pathology Today." The owners of those linked sites, and not FSP, own the intellectual property rights to the material on the linked sites. FSP cannot certify the accuracy of material published on linked sites. Additionally, the contents of this e-Newsletter and the above referenced links, including any advice, suggestions, and/or recommendations have NOT been generated as part of any professional evaluation.

The authors, editors, webmasters, and the FSP Board of Directors affiliated with the "Florida Pathology Today" e-Newsletter shall not be liable to anyone for any loss or injury caused in whole or in part by its negligence or contingencies beyond its control in procuring, compiling, interpreting, reporting or delivering this e-Newsletter and any information included in this e-Newsletter.

Under no circumstances will the authors, editors, webmasters, and the FSP Board of Directors affiliated with the "Florida Pathology Today" be liable to you or anyone else for any decision made or any action taken by you or anyone else in reliance on such information or view, or for any incidental, consequential, special, or similar damages even if advised of the possibility of such damages.

The above warranties are the only warranties of any kind either expressed or implied, including warranties of merchantability or fitness for any particular purpose.

 



Pathology Today
Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Esther Cho, Content Editor, 469.420.2671  
Contribute news


Learn how to add us to your safe sender list so our emails get to your inbox.

This edition of Pathology Today was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here — it's free!

Recent issues

July 9, 2014
June 25, 2014






7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063